Ben Kim is a Partner at Playground Global where he helps identify the founders and companies that are revolutionizing engineered biology. At Playground, he has sourced and led investments into companies including Atomic AI, Amber Bio, Insamo, Infinimmune, Outpace Bio, Manifold Bio and Lassogen, where he also sits as a Board Observer. In 2022, Ben led investments into two breakthrough biotech companies, currently operating in stealth. Playground’s Life Sciences portfolio includes mRNA therapeutics (Strand Thx) and genome sequencing (Ultima Genomics). 

Prior to Playground, Ben was a PhD graduate student and an NSF Fellow at Stanford University, where he studied Bioengineering and Biomedical Engineering.